Trial Profile
An Open-label Long-term Extension Trial From Late Phase II of SPM 962 (243-07-003) in Patients With Restless Legs Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2016
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 19 Jul 2016 New trial record